I guess its safe to say that January was a bad month on relatively below avg volume...And February so far ...well equilibrium can be a bitch...imao...r

Hancock sold 5k shrs worth of excerised options...https://www.sec.gov/Archives/edgar/data/704562/000168316822000673/xslF345X03/ownership.xml ...r

Interesting that nasdaq site has Blackrock showing ownership of 4,384,513 shrs when they just filed their amended 13g last week listing 9,577,705 shrs?...if everything remained status quo on other institutional holdings then the % would jump to approx 96% w/those 5 mil shares factored in...r

At some point the large stakeholders will have to defend their position...imao...r

Ahh the Lizzy Holmes school of PR Management 101 you mean?...r

Nothing on drudge or zerohedge....if its on the fringe it'll show up there first usually...r

Debtor
Jeanette M. Bleecker

Fargo, ND 58103
CASS-ND

aka Jeanette M. Bona
aka Jeanette M. Bergemann

represented by Angie Shambour
(See above for address)
ht to bcs paladin...r

So he knows where the bodies are buried?...r

Considering that Fidel and Blackrock own about a 1/3rd of the cdmo shares i would think that they make any entity looking for an exit ramp on low volume periods to pay dearly...think Hotel California... you can check out anytime you want but you can never leave (cheaply) :>) ...imao...r

I see Ziebell sold off 6829 shrs that weren't ESOP shrs @ $30.26 avg...has 7429 shrs left...r

Zacks is really pushing cdmo...another article this am which is a repeat of yesterdays glowing nonsense...imao...r

Anyone hear who the provided the nanoparticle for the Army clinical trial vaccine in the news today?...r

Esop shares being excercised for non-execs?...r

Sorry but i was referring to the entire market tomorrow....r

Ah but option expirations enters the picture....r

YEAH...its ok for big guys to cry...imao...r

Archie...recv'd this email from st judes yesterday... A new therapy developed at St. Jude Children’s Research Hospital has significantly increased the survival rate for high-risk neuroblastoma patients, according to an important new study published this week.
Here’s how Dr. Wayne Furman, a St. Jude faculty member and the first and corresponding author of the study describes the results: “I have treated high-risk neuroblastoma for 30 years, and I have never seen results like this in high-risk patients. This is the best result published to date for patients with high-risk neuroblastoma, period.”
Neuroblastoma is a cancer of the nervous system that is diagnosed in about 700 people in the United States annually. Sadly, most of those patients are 5 years old or younger. Despite aggressive therapy, nearly half of patients diagnosed with high-risk neuroblastoma die of their disease.
But researchers at St. Jude have found that survival rates rose significantly when a novel monoclonal antibody manufactured on the St. Jude campus was used throughout therapy. Three-year disease-free survival was nearly 74% for newly diagnosed high-risk neuroblastoma patients enrolled in the clinical trial.
Those numbers are far more than statistics: They mean that, thanks to your generous support, more families can have hope that their children will live long and healthy lives.
But the research doesn’t stop here: This St. Jude study included 64 patients. If the results are confirmed in a larger, multi-institutional clinical trial, the approach may rewrite clinical care for neuroblastoma.
That’s the impact that your support is having on patients around the globe. More work remains, and with your continued support, St. Jude won’t stop until no child dies of cancer.
With hope and great appreciation.
.....r

PSA for board members 401/ira/trading online accts... https://cdn.statcdn.com/Infographic/images/normal/26298.jpeg ...r

Its also dated as 10/31/21...that accounts for a good hunk of the 13.7 mil shrs traded on 10/28...r

Nazdaq has 4.834 mil as of 9/30...r

Looks like fidelity added 31k shrs (now 8.591 mil)...r

I found that $28 figure interesting when the note was announced...i don't think that was derived from a dart throwing contest... If that value was assigned based a $270 mil rev projection and then the new viral vector announcement added an additional 37% to the total revs...comes to exactly the figure that 4our had the other day (to the penny) on the breakout target...$38.36...imao...r

The pr also included a statement that they may be operational in the new facility by 1st quarter of new fiscal year (starts 5/1/22)...I find that as much as a shiny object as the new hire bio...imao...r

Inst positions beginning to update...of note for major holders so far is altravue up 12.68%...r

I think we all owe John Stafford a ton of gratitude to be we are today...considering where we were 4 yrs ago...imao...r

They took out my april 25's...finally...r

So was Tappan's selloff part of the 5 million shares traded on 10/26?...the same same date of the filing?...r

Btw...ADCT will host a conference call and live webcast on Tuesday, November 2, 2021, at 8:30 a.m. EDT to report financial results for the third quarter 2021 and provide business updates. ...r

Amazing that no calls in april have traded?...imao...r

As a comparison of scale..the Merck viral vector new addition is costing $832/sq ft to build (140k sq ft)...the Costa Mesa facility is going to cost $1415/sq ft to build (used the $75 mil figure)...which leads me to ask why aren't p&l breakdowns done on a "per sq ft basis" for this sector?...i know that this metric is prevalent in the retail industry...imao....r

Anyone see the options timestamped 2:41 am today?...r

Btw saw this yesterday...Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy ...Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors ...Enables suspension production of viral vectors up to 1,000-liter scale... https://www.prnewswire.com/in/news-releases/merck-completes-new-viral-vector-contract-development-manufacturing-facility-for-gene-therapy-871948996.html ...r

I believe you would a need a proxy vote to increase the amount of shares authorized to cover the forward split...maybe next august it will be on the DEF14A filing...or one of the analyst might ask that question on a 2022 cc...imao...r

If someone were to ask me how to describe in 2 words the share price trends over the last year or so i would use a "bulimic glutton" as an appropriate description...imao...r

Catalent Pharma Solutions CEO on his company's 'record year,' booster shot plans John Chiminski, the CEO of Catalent Pharma Solutions, which manufactures COVID vaccines for Moderna, Johnson & Johnson and AstraZeneca, describes the supply chain challenges last year and how his company overcame them... https://video.foxbusiness.com/v/6270168905001/#&_intcmp=hp1r_19,hp1r
...could be our suitor someday?....r

Proxy should be out soon...wonder if there will be any surprises on the share authorization issue?....r

Is there a good time today that he could call ya?...r

JB..think about all the possible angles to your question...imao...r

Check out the Fintel short sell share availability...r

What was the dilution factor on the Note @ $28?...r